Goldman Sachs Adds Four European Stocks To Conviction List

I still remember the first time a conviction list actually changed how I sized a position. Not because the price target was heroic. Because the note admitted, almost in passing, that the stock had already done most of the year’s earnings work and the market was still treating it like a broken story. That mismatch is the whole game. This month, a major Wall Street bank refreshed its European directors’ cut and dropped four new names onto the page: a Spanish renewable developer, a Swiss dental implant maker, a German property-search platform, and a Dutch specialty chemicals distributor. Three other names came off. Six stocks on the wider list still carry upside calls above 70 percent, including a German defense name the desk thinks could more than double from here.

If you only read the headlines, this looks like another broker reshuffle. It is not quite that. Conviction lists are a strange hybrid of marketing and memory. Analysts fight to get a name on them. Portfolio managers scan the additions and the deletions more carefully than the unchanged holdings, because change is where the argument is freshest. I have found that the removals often tell you more about the house view than the shiny new buys. A stock can leave because the thesis worked, because it broke, or because something quieter shifted in the risk budget. Worth knowing which.

What follows is a plain reading of the four additions, the three exits, and the two eye-watering upside calls that did not need to be new to dominate the conversation. No fairy dust. Price targets are opinions with a spreadsheet attached. Treat them that way.

What The October Conviction Cut Is Really Saying

A directors’ cut is not the full research universe. It is the short list the bank wants clients to remember when the month gets noisy. Europe in early October is noisy enough. Energy prices are twitchy. Rate-cut hopes keep getting rewritten. Industrial orders are patchy. Housing markets are thawing in some cities and frozen in others. Into that mix, the desk chose exposure that is oddly specific: power infrastructure with a data-center angle, premium medical devices, a digital tollbooth on German rentals, and a distributor that lives on formulation know-how rather than commodity tons.

That mix is not a macro bet on “Europe up.” It is a bet on four different scarcity stories. Grid access. Clinical trust. Proprietary listing data. Specialty ingredients that customers do not want to requalify every quarter. Scarcity is harder to fake than a growth slide.

A price target is a story with a number on it. The useful part is usually the story, not the number.

– A portfolio manager I still argue with

Before the names, a quick map of the upside the bank is willing to print. These are 12-month targets as framed in the latest cut, not promises.

Notice the spread. The new names cluster between roughly 38 and 64 percent. The fireworks sit with names that were already loved. That tells you the October refresh is about rebuilding the middle of the list, not inventing a new moonshot. In my experience, that is the healthier kind of update. Moonshots age badly in client reviews.

Solaria And The Quiet Power Of Grid Access

Solaria designs and installs solar, thermal, photovoltaic and wind plants. Madrid is home base. The bank’s target is 25 euros, which it frames as about 52 percent upside from the level that triggered the note. The stock has been ugly enough, recently, that the sell-off itself is part of the pitch. Valuation, the argument goes, looks largely de-risked. I am always a little allergic to that phrase. Markets can de-risk a stock and then de-risk it again. Still, the operating claim underneath is more interesting than the adjective.

Management has already delivered roughly 65 percent of full-year EBITDA guidance. That is not a victory lap. It is a timing fact. If the back half holds, the year is not a hope. Normalized hydro output and firmer gas prices are supposed to help the second half. Power markets do not care about your slide deck, so that support is conditional. What the analyst seems to be buying is not a one-quarter weather print. It is optional upside from two places the power system actually needs: data centers and battery storage.

Here is the bit I keep turning over. If a developer can bundle land, grid access and energy into a long-term contract with a data-center customer, the return profile changes. The bank talks about high-teens returns on that kind of package. Land without a grid connection is a field. A grid connection without a buyer is a stranded asset with a pretty substation. The bundle is the product. Europe’s data-center buildout is real, and it is colliding with connection queues that already run for years in several countries. A company that already owns the awkward parts, permits, land, interconnection, has something harder to replicate than a panel price.

• About 65 percent of full-year EBITDA guidance already in hand, which lowers the “hope” share of the year.
• Second-half support tied to normalized hydro and firmer gas, which can fade if weather or fuel flips.
• Data-center bundling of land, grid and power as the strategic catalyst, with high-teens returns cited if contracts stick.
• Battery storage as a second leg, useful if volatility in power prices stays a feature rather than a bug.
• A recent sell-off that the desk reads as an entry, not a warning. That reading can be wrong.

Renewable developers have a habit of looking cheap right before a capital raise, a permitting delay, or a power-price air pocket. Solaria is not immune. Interest rates still matter because these assets are long-duration cash flows wearing a hard hat. If European yields back up, the multiple does not get a free pass just because a research note used the word de-risked. Perhaps the most interesting aspect is not the 25 euro target. It is whether grid-constrained power becomes a toll road. Toll roads get paid. Fields do not.

I would watch three things and ignore the rest of the noise. Contracted versus merchant exposure. The pace of interconnection, not the press release about interconnection. And whether data-center counterparties are signing multi-year offtake or just touring sites. Touring is not revenue.

Straumann At A Valuation The Market Has Not Seen In Years

Straumann is the Zurich name in dental implants and restorative dentistry. The bank puts a 125 Swiss franc target on it, about 38 percent upside, and notes that the shares trade near decade lows relative to their own history, around 24 times next-twelve-month earnings. Decade-low relative valuation is one of those phrases that sounds like a gift and sometimes is a trap. Cheap versus yourself can still be expensive versus the next five years of volume.

The constructive case is straightforward. Sales growth is expected to pick up. Business conditions in China are described as improving. Losses in the orthodontics arm are expected to narrow. Straumann has been one of the faster growers in restorative dentistry, which is a polite way of saying dentists kept specifying the brand when patients could be talked into a better implant rather than a cheaper one. Brand in this niche is not a logo. It is a clinician’s reluctance to switch a system mid-career.

The same note does not pretend the path is clean. U.S. demand for dental procedures has softened as living costs rise. Elective work gets postponed when the credit card already hurts. China carries a different risk: government price reforms. Anyone who lived through medical-device tendering in that market knows a reform can reprice a category faster than a sales force can retrain. Both headwinds can be true at once. A stock can be statistically cheap and still disappoint if procedure volumes stall on one side of the Pacific and tenders bite on the other.

In medical devices, the moat is often the surgeon’s muscle memory. It is also the first thing a tender tries to ignore.

Why put it on a conviction list now, then? Because the valuation already prices a gloomy version of those risks, and the operating deltas the analyst cares about, China stabilization, narrower orthodontics losses, a return to faster growth, do not need a boom. They need a stop to the deterioration. That is a lower bar than “dentistry is back.” I like lower bars. They get cleared more often.

A practical way to hold this name in your head: implants are procedure-linked, partly elective, and branded. They behave a bit like a consumer health stock and a bit like a hospital capex stock. When household budgets crack, the consumer half shows up first. When hospital and clinic confidence returns, the professional half follows with a lag. The 24 times multiple says the market is paying for the lag, not the recovery. If the lag shortens, 38 percent is not fantasy. If U.S. deferrals deepen into next year, the multiple can stay “historically cheap” for a historically long time.

Scout24 And The Toll On German Rentals

Scout24 runs ImmoScout24 across the German and Austrian housing markets. The 12-month target is 108 euros, framed as roughly 64 percent upside. That is the punchiest of the four new additions, and it rests on a very unglamorous fact. About 21.7 million German households live in rented accommodation. That is not a total addressable market slide. That is a country where renting is the default, not the fallback.

Private subscribers are about 20 percent of revenue today. The bank expects that pocket to grow, helped by products such as deposit guarantees, and it thinks the company can hit 700,000 private subscribers by 2028, ahead of what the wider market is modeling. The product family sits under a Living suite aimed at tenants, not just at agents listing flats. If you have ever tried to rent in a tight German city, you already understand the psychology. The listing site is not a nice-to-have. It is the queue.

Two further planks hold the thesis up. First, operating leverage: revenue is expected to grow faster than costs, so profit improves without a heroic margin story. Second, lower debt could free cash for buybacks, and the franchise is described as an attractive target if deal activity in the sector keeps rising. I would not underwrite an acquisition premium as if it were a dividend. Bidders are a maybe. Buybacks funded by a cleaner balance sheet are a process you can actually track.

The competitive worry everyone reaches for now is artificial intelligence. Summaries, chat windows, a model that tells you the flat is fine. The desk’s answer is that a strong position in the German real estate ecosystem, plus proprietary data, is a meaningful moat against generic summaries. I think that answer is half right. A summary can describe a listing. It cannot yet be the place where landlords, tenants, agents and verification all agree to meet. Marketplaces die when the liquidity leaves, not when a chatbot gets clever. Liquidity in German rentals is still concentrated.

1. Private subscribers, roughly a fifth of revenue, are the growth wedge, with deposit-style products as the hook.
2. The rental base, 21.7 million households, is the pond. You do not need all of it. You need the anxious slice that will pay to stand out.
3. A 700,000 private-subscriber goal by 2028 is the number to circle, because the bank says it sits ahead of consensus.
4. Cost growth lagging revenue is the margin path. If that gap closes, the upside case thins fast.
5. Buybacks and possible sector deals are the capital-return kicker, not the core.

Housing platforms are sentimental stocks. They trade like tech when rates fall and like local classifieds when rates rise. German mortgage rates and transaction volumes will yank the agent side around. The tenant side is stickier, which is why the private-subscriber push matters more than another brand campaign. If I were stress-testing this, I would ask a blunt question. What happens to willingness to pay if rental markets loosen and the queue shortens? Scarcity of flats is part of the product. A looser market is not fatal. It is a slower market.

IMCD And The Case For Sticky Specialty Margins

IMCD distributes specialty chemicals out of Rotterdam. The 12-month target is 133 euros, with total return potential over the period put around 40 percent. The macro tailwind cited is almost old-fashioned: oil price inflation and supply-chain volatility, both of which the company can pass on to customers. Pass-through is the distributor’s superpower and its curse. You look clever when inputs jump. You look ordinary when they do not.

The distinction the analyst wants you to hold is specialty versus commodity. IMCD leans into higher-value ingredients, plus services such as formulation work. That mix, the argument says, makes the profitability boost stickier than in bulk chemicals, and it insulates the firm from Chinese competition in the near term. Commodity distributors live on basis points and logistics. Specialty distributors live on whether the customer’s recipe still works if they swap supplier. Recipes are sticky. Logistics are not.

Then comes the number that should make you sit up. EBITA margins are projected to rise from 10.4 percent in 2025 to an estimated 27 percent in 2027. I will say this plainly, because a human reading a note should. That is an enormous step-up for a distribution business. Either the mix shift is extraordinary, the base year is unusually depressed, or the estimate is doing a lot of hoping. Maybe more than one of those. A conviction-list addition does not require you to swallow the outer year whole. It requires you to decide whether the direction is right.

How I would split the IMCD debate:
  Pass-through of oil and freight swings  -> real, but cyclical
  Formulation services                    -> stickier, slower
  Margin path toward the high 20s         -> the part that needs proof
  Chinese competition                     -> delayed, not cancelled

Near-term insulation from lower-cost Asian supply is plausible in regulated or specification-heavy end markets. Food ingredients, personal care, pharma-adjacent chemicals, coatings where a reformulation triggers a customer audit. Those audits are a moat made of paperwork. They do not last forever. They last long enough to matter for a 12-month target. Beyond that, price gaps have a way of finding a door.

If you own distributors, you already know the tell. Gross margin per unit and the share of revenue that comes with a technical service attached. When service attach rises, the 27 percent dream becomes less absurd. When it is just price pass-through on a hot input, the dream expires with the input cycle. I would rather underwrite the service than the oil price.

The Three Names That Left, And Why Exits Matter

Naturgy, Norsk Hydro and Smith & Nephew came off the latest breakdown. Different sectors, different reasons you can imagine, and the note as circulated does not walk through a full autopsy. That absence is itself information. Lists often explain additions at length and exits in a line. Clients should reverse the emphasis.

A utility-like energy name, an aluminum and power-linked industrial, and an orthopedics company. One reading is simple housekeeping. The book needed room for Solaria, Straumann, Scout24 and IMCD, and something had to give. Another reading is thematic. Power is being expressed through a developer with grid optionality rather than through an integrated gas and networks name. Materials exposure is being expressed through specialty distribution rather than through a primary metal. Medical exposure is shifting from orthopedics toward dental implants. I do not know that this was the intent. I know the resulting shape of the list looks like that.

Exits are not sells for your account. A name can leave a showcase list because the upside to target compressed after a rally, which is success, or because the thesis cracked, which is not. Without the exit note, assume neither. Check whether your original reason for holding still exists. Lists are a menu. They are not your kitchen.

The Upside Calls That Steal The Page

Six stocks on the wider cut carry upside above 70 percent. Two of them will get all the airtime. Rheinmetall, the German defense group, is assigned upside of up to 143 percent. Adyen, the Dutch payments and commerce infrastructure company, is assigned about 111 percent. Neither had to be a new addition to dominate a Friday morning scroll.

Defense first, because the number is the one people will quote at dinner. European rearmament is no longer a conference theme. It is a budget line, a factory expansion, and a multi-year order book. A 143 percent upside call says the desk believes the market is still pricing a shorter cycle than the procurement reality. That can be right and still be a terrible entry if you buy the headline after a vertical move. Defense stocks have already taught a generation of investors that “structurally higher spending” and “up every month” are not the same sentence. Backlogs are lumpy. Politics is lumpy. Margins on new programs are not the margins on mature ones.

Payments next. Adyen’s path from market darling to disappointment to rehabilitation is a case study in what happens when growth stocks miss a quarter and the multiple does the violence. An upside call above 100 percent is a statement that the franchise, take rate, enterprise win rate, operating discipline, is intact and the stock is not. Maybe. Payments businesses are wonderful until a volume air pocket or a pricing fight shows up. I have a bias here, and I will own it. I trust payment infrastructure more than I trust any single year’s take-rate guide. I do not trust a triple-digit target as a timeline.

Put the two next to the new additions and the list has a personality. Scarce physical capacity in defense and power. Scarce clinical trust in implants. Scarce marketplace liquidity in rentals. Scarce formulation skill in chemicals. Scarce merchant trust in payments. The bank is not buying “Europe.” It is buying bottlenecks.

How A Working Investor Should Actually Use This List

Conviction lists are useful the way a good editor is useful. They force a choice. They are dangerous the way a good editor is dangerous. You start mistaking the shortlist for the world. Here is the filter I use, and you can steal it without paying me a management fee.

• Separate the target from the mechanism. If you cannot explain the mechanism in two sentences, you do not have a thesis. You have a PDF.
• Ask what is already in the price. Straumann near a decade-low relative multiple is a different animal from a defense name everyone already owns in size.
• Check the balance sheet before the story. Scout24’s buyback angle depends on debt coming down. Solaria’s bundling angle depends on not getting diluted into oblivion.
• Give the outer-year margin a haircut. IMCD’s path toward 27 percent EBITA is the number I would haircut first, on purpose, to see if the equity case survives a lesser improvement.
• Treat removals as a prompt to reread, not as an instruction to sell.

Position sizing is where most people quietly lose. A 52 percent upside case is not a 52 percent position. European single names gap on local headlines, on a rate print out of Frankfurt, on a Chinese tender, on a North Sea weather system. I would rather own a basket of the mechanisms, power scarcity, clinical brands, marketplace tolls, specialty distribution, than marry one target. The list even hands you the basket. You do not have to take every seat.

Time horizon matters more than people admit in October. These are 12-month targets. A data-center power contract can slip a year without the strategic logic dying. A dental volume recovery can slip two quarters. If your money is needed in April, you are not the client this note was written for. If your money can sit through a dull winter, the entry points created by recent weakness in a couple of these names are the actual gift. Weakness is not a thesis. It is a price.

A simple screen before you add any name from a showcase list:
Mechanism clear? Balance sheet survivable? Upside not only from the multiple? Exit plan written while calm?

The Risks The Upside Column Leaves In The Footnotes

Start with rates. All four new names have duration hiding in them. Solaria through asset yields. Straumann through a premium multiple that expands when real yields fall. Scout24 through housing turnover and the discount rate on a platform. IMCD less so, but even distributors get rerated when the cycle turns and people remember they are not software. A hawkish surprise does not need to kill the businesses. It needs to kill the multiple you just paid.

Then politics and policy. Chinese price reform sits on Straumann’s shoulder. Grid policy and permitting sit on Solaria’s. German housing regulation can help or hurt a rental marketplace depending on which lobby wins the month. Specialty chemicals live downstream of environmental rules that can ban an ingredient or, just as often, make the qualified supplier more valuable. Policy is not background. In this quartet it is an input.

Currency is the boring risk that still moves the account. Swiss francs, euros, and whatever your base currency is. A 38 percent Swiss franc upside can be a smaller number after translation if the franc does what the franc sometimes does. Total-return targets that ignore your own currency are targets for someone else.

Execution risk is the one I trust least to be priced. Scout24 has to actually land those private subscribers, not just describe the Living suite. Solaria has to turn site tours into contracts. Straumann has to narrow orthodontics losses without starving the core. IMCD has to show that margins are mix, not a commodity spike in a nice suit. Miss two quarters of the mechanism and the conviction label will not save the drawdown. Labels do not place bids.

There is also crowding. Defense and high-quality European compounders have been a crowded room. Adding a beloved payments name with a triple-digit upside call does not make the room less crowded. The less obvious additions, a dental name at a depressed relative multiple, a distributor, a solar developer after a sell-off, are where crowding is lighter. Lighter crowding is not the same as being right. It does mean you are less likely to be the last guest at a party that started in January.

A Cleaner Way To Hold The Four Ideas

If I had to explain this refresh to a skeptical friend over coffee, I would skip the targets and use one line each.

Solaria is a bet that grid access plus land becomes a product data centers will pay up for, and that the stock already discounts a dull version of the power year. Straumann is a bet that procedure growth stabilizes and China stops getting worse, at a multiple the shares have not worn in years. Scout24 is a bet that German tenants will keep paying for a place in the queue, and that private subscriptions scale faster than the street models. IMCD is a bet that specialty formulation is a better business than bulk distribution, with a margin forecast you should only half believe until the numbers show up.

None of those lines require you to think the bank is omniscient. They require you to think the mechanism is plausible and the price is not already perfect. On at least two of the four, the recent tape suggests the price is not perfect. Perfect prices do not get 50 percent upside stamped on them by a desk that has to show its face next month.

Would I buy all four on a Monday open because a list said so? No. I have never had a good result doing that. I would put Solaria and Straumann on a watchlist with hard triggers, Scout24 on a slower accumulation if the subscriber prints keep beating the path to 700,000, and IMCD only after I had torn up the 2027 margin and replaced it with something I could defend in an argument. Rheinmetall and Adyen I would treat as already-discovered stories where the upside case is loud and the entry discipline has to be louder.

What I Will Be Watching Into Year End

For Solaria, any signed data-center related offtake, and whether second-half power conditions really do the work the note expects. For Straumann, U.S. procedure commentary and the tone on Chinese pricing, not the slogan about improving conditions. For Scout24, private subscriber additions and whether deposit-style products are pulling their weight or just decorating the slide. For IMCD, gross margin and the service attach rate, because that is the only honest path toward a fatter EBITA margin.

Around them, the exits deserve a second look in your own book. If you held the aluminum name for a power-price kicker, ask whether that kicker still exists. If you held the orthopedics name as your medical exposure, notice that the showcase list just preferred teeth to joints. Preferences are not facts. They are a hint about where incremental research hours are going.

Europe does not need a single narrative to make money in from here. It needs a few places where the constraint is physical, regulatory, or behavioral, and where the share price has not fully rented that constraint out to you at a luxury price. This October cut is one desk’s attempt to point at four of those places, while still keeping the dramatic defense and payments calls on the poster. Take the poster down. Read the mechanisms. Then decide what, if anything, belongs in the account you actually have to live with.

Lists change every month. The bottlenecks do not. That is the part worth keeping.